7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 
      
    		                   
      cash flows from operating activities:
    		                   
      net income
    		-57,119,000 -34,727,000 -45,621,000  -51,107,000 -36,930,000 -40,610,000      26,624,000 -6,785,000 168,573,000  -21,382,000 -2,323,000 117,221,000 
      depreciation of property and equipment
    		4,306,000 4,542,000 4,409,000 2,100,000 3,834,000 3,448,000 3,155,000 3,884,000 3,064,000 2,952,000 2,858,000 2,741,000 2,531,000 2,290,000 1,391,000 1,343,000 1,163,000 1,057,000 840,000 
      amortization and impairment of intangible assets
    		940,000   10,464,000 33,085,000               
      amortization of operating lease right-of-use assets
    		1,990,000 1,589,000 1,274,000 1,336,000 1,376,000 1,515,000 1,922,000 1,573,000 1,674,000 1,646,000 1,606,000 1,573,000 1,566,000 1,144,000 976,000 890,000    
      stock-based compensation
    		13,895,000 14,207,000 14,786,000 15,226,000 17,164,000 17,782,000 17,409,000 16,448,000 15,862,000 16,399,000 15,474,000 13,323,000 11,754,000 12,113,000 12,291,000 9,038,000 7,708,000 8,473,000 5,427,000 
      fair value (gain)/loss on contingent consideration
    		                   
      other
    		1,655,000     -9,900,000 1,707,000 6,631,000 -1,925,000 -795,000 -3,634,000 5,243,000 3,602,000 294,000 -592,000 2,682,000 1,307,000 -228,000 -191,000 
      changes in operating assets and liabilities:
    		                   
      research fees and grants receivable
    		-3,433,000 -11,391,000 -1,133,000  -19,824,000 -15,858,000 -18,576,000             
      income taxes payable
    		  -4,408,000  -2,756,000 -2,771,000 -3,182,000  5,801,000 35,498,000 -12,614,000 -53,675,000 -87,185,000 -17,714,000 69,965,000 16,033,000 767,000 -24,207,000 -6,123,000 
      accounts payable and accrued liabilities
    		5,070,000 -3,947,000 -3,409,000 6,617,000 4,148,000 4,748,000 -4,878,000  975,000 2,951,000 -5,778,000 2,217,000 731,000 -2,633,000 751,000 1,713,000 3,327,000 1,554,000 -5,194,000 
      deferred revenue
    		-7,045,000 -3,952,000 13,313,000 5,543,000 -692,000 -4,765,000 -8,017,000 -6,738,000 -2,368,000 -965,000 -3,905,000 10,277,000 -1,115,000 -3,920,000 941,000 -427,000 4,203,000 -1,238,000 6,086,000 
      deferred grant income
    		-1,153,000 -461,000 -1,220,000 3,296,000 10,914,000 8,479,000 11,278,000 9,144,000 4,811,000        4,975,000   
      other assets
    		628,000 6,130,000 7,320,000 4,946,000 2,481,000 2,132,000 -3,605,000 4,661,000 9,152,000 1,230,000 -6,063,000  2,913,000 3,418,000 -7,557,000  299,000   
      net cash from operating activities
    		-52,594,000 -32,404,000 -11,554,000 -8,000,000 -28,882,000 -29,966,000 -41,708,000 -19,611,000 -106,000 19,903,000 -44,063,000 30,912,000 -126,786,000 273,015,000 100,219,000 -16,712,000 -5,932,000 157,683,000 109,545,000 
      capex
    		-8,928,000 -13,365,000 -10,636,000 -15,630,000 -18,516,000 -20,110,000 -24,140,000 -14,431,000 -20,331,000 -27,201,000 -14,984,000 -12,330,000 -12,513,000 -31,322,000 -14,495,000 -9,430,000 -8,574,000 -36,804,000 -3,644,000 
      free cash flows
    		-61,522,000 -45,769,000 -22,190,000 -23,630,000 -47,398,000 -50,076,000 -65,848,000 -34,042,000 -20,437,000 -7,298,000 -59,047,000 18,582,000 -139,299,000 241,693,000 85,724,000 -26,142,000 -14,506,000 120,879,000 105,901,000 
      cash flows from investing activities:
    		                   
      purchases of property and equipment
    		-8,928,000 -13,365,000 -10,636,000 -15,630,000 -18,516,000 -20,110,000 -24,140,000 -14,431,000 -20,331,000 -27,201,000 -14,984,000 -12,330,000 -12,513,000 -31,322,000 -14,495,000 -9,430,000 -8,574,000 -36,804,000 -3,644,000 
      purchase of marketable securities
    		-33,162,000 -126,552,000 -164,990,000 -152,837,000 -186,242,000 -176,636,000 -249,371,000 -276,836,000 -215,783,000 -168,139,000 -360,752,000  -536,124,000 -82,532,000 -51,774,000 -29,396,000    
      proceeds from marketable securities
    		83,099,000 113,410,000 190,027,000 201,893,000 196,604,000 232,840,000 306,545,000 268,024,000 220,099,000 160,176,000 262,638,000 92,393,000 272,430,000 88,514,000 57,294,000 18,081,000    
      receipt of grant funding
    		918,000 5,430,000 1,018,000 6,558,000 9,400,000 12,582,000 7,168,000 10,288,000 7,330,000 5,000,000 2,693,000 2,334,000 6,002,000 5,502,000 2,596,000 22,814,000 5,287,000   
      long-term investments and other assets
    		-2,988,000 -8,182,000 -5,601,000 -2,611,000 9,588,000 8,335,000 -4,385,000 -7,892,000 0 -2,022,000 -34,735,000  -5,713,000 0 -11,657,000     
      investment in equity accounted investees
    		-2,451,000 -2,552,000 -1,883,000  -7,136,000 -4,913,000 -5,907,000             
      net cash from investing activities
    		36,488,000 -31,811,000 7,935,000 35,703,000 3,698,000 52,098,000 29,910,000 -24,323,000 -12,786,000 -34,390,000 -149,609,000 -17,063,000 -281,994,000 -27,197,000 -26,371,000 -1,149,000 -269,626,000 -45,633,000 -15,839,000 
      cash flows from financing activities:
    		                   
      payment of liability for in-licensing agreement and other
    		  -178,000 -177,000 -184,000 -183,000 -185,000             
      proceeds from other liabilities and exercise of stock options
    		                   
      net cash from financing activities
    		7,372,000 -3,375,000 5,970,000 4,142,000 3,145,000 2,651,000 2,831,000 3,765,000 6,630,000 419,000 -458,000 349,000 -19,000 1,173,000 -3,131,000 1,834,000 898,000 -5,075,000 -1,543,000 
      effect of exchange rate changes on cash and cash equivalents
    		-544,000 761,000 590,000 -2,160,000 367,000 -43,000 -781,000 1,068,000 -1,063,000 797,000 -213,000 364,000 -8,552,000 -1,207,000 -204,000 -525,000 -217,000 -199,000 -484,000 
      decrease in cash and cash equivalents
    		      -9,748,000 -39,101,000            
      cash and cash equivalents and restricted cash, beginning of period
    		0 0 183,615,000 0 0 0 160,610,000 -1,000 0 1,000 414,650,000  0 0 501,142,000     
      cash and cash equivalents and restricted cash, end of period
    		-9,278,000 -66,829,000 186,556,000 29,685,000 -21,672,000 24,740,000 150,862,000 -39,102,000 -7,325,000 -13,270,000 220,307,000  -417,351,000 245,784,000 571,655,000     
      restricted cash included in other assets
    		0 0 2,290,000 0 0 0 2,290,000 0 0 0 2,290,000  4,939,000       
      total cash, cash equivalents, and restricted cash shown on the balance sheet
    		-9,278,000 -66,829,000 184,266,000 29,685,000 -21,672,000 24,740,000 148,572,000 -39,102,000 -7,325,000           
      supplemental disclosure of non-cash investing and financing activities
    		                   
      property and equipment in accounts payable
    		-2,276,000 1,773,000 10,960,000 -3,222,000 45,000 -2,710,000 18,654,000 677,000 1,230,000 2,800,000 8,918,000         
      right-of-use assets obtained in exchange for operating lease obligation
    		6,331,000 66,426,000 3,361,000 -334,000 1,780,000 345,000 107,000 -2,387,000 641,000 821,000 2,124,000 4,455,000 47,035,000 -1,454,000 658,000 9,662,000 -2,597,000 15,385,000 14,188,000 
      fair value gain on contingent consideration
    		                   
      income taxes receivable
    		                   
      payment of contingent consideration and other
    		                   
      proceeds from long-term liabilities and exercise of stock options
    		 5,505,000 6,148,000                 
      increase in cash and cash equivalents
    		 -66,829,000 2,941,000       -13,271,000 -194,343,000   245,784,000 70,513,000 -16,552,000 -274,877,000 106,776,000 91,679,000 
      amortization of intangible assets
    		  922,000    1,689,000  2,671,000 2,658,000 2,656,000  2,631,000 2,607,000 2,606,000 2,630,000 2,502,000 2,465,000 2,465,000 
      fair value gain on contingent consideration and other
    		  2,213,000                 
      net earnings
    		       -47,150,000 -28,610,000 -30,528,000 -40,110,000         
      fair value (gain) loss on contingent consideration and investments
    		                   
      research fee and grant receivable
    		       -10,438,000            
      accrued royalties receivable
    		       0 13,000 0 9,260,000 85,205,000 -62,617,000 274,497,000 -167,914,000 -134,463,000 21,559,000 145,907,000 26,861,000 
      income taxes (payable) receivable
    		                   
      purchase of intangible assets
    		       0    0        
      investment in and loans to equity accounted investees
    		       -3,476,000 -3,541,000 -2,204,000 -4,469,000 -5,909,000 -4,076,000 -7,359,000 -8,335,000 -3,218,000 -6,595,000   
      fair value gain on contingent consideration and investments
    		                   
      deferred income tax and other
    		                   
      accrued royalties payable
    		        0 0 -16,253,000 1,524,000 -32,733,000 5,192,000 22,857,000 21,911,000 -22,925,000 3,511,000 -7,134,000 
      proceeds from long-term liabilities
    		    3,102,000 2,373,000 2,124,000             
      proceeds from exercise of stock options
    		    227,000 461,000 892,000             
      deferred tax (expense) recovery
    		                   
      change in fair value of contingent consideration and investments
    		                   
      accounts payable and other liabilities
    		                   
      acquisitions
    		                   
      payment of liability for in-licensing agreement, contingent consideration, and other
    		       -185,000            
      proceeds from long-term debt and exercise of stock options
    		          490,000         
      accounts and accrued research fees receivable
    		         -32,184,000 7,915,000 -19,040,000 3,288,000 1,788,000 -8,751,000 -3,057,000 -5,990,000 1,734,000 -30,073,000 
      payment of liability for in-licensing agreement and contingent consideration
    		         271,000 -948,000         
      proceeds (repayment) from long-term debt and exercise of stock options
    		                   
      deferred grant revenue
    		          4,525,000 2,634,000 1,224,000 724,000 4,682,000     
      total cash, cash equivalents and restricted cash shown on the balance sheet
    		          218,017,000         
      deferred tax expense
    		               1,249,000 -4,023,000 133,000 623,000 
      operating lease liabilities
    		               -451,000 37,000   
      other operating assets and liabilities
    		                   
      purchases of marketable securities
    		                   
      acquisitions, net of cash acquired
    		                   
      long-term investments and other
    		                   
      repayment of long-term debt and contingent consideration
    		           0 -250,000 -1,000 -72,000     
      proceeds from convertible debentures
    		                   
      net proceeds from issuance of common shares
    		                   
      proceeds from issuance of preferred shares - series a1 and a2 financing
    		                   
      cash and cash equivalents and restricted cash, beginning of year
    		                   
      cash and cash equivalents and restricted cash, end of year
    		                   
      restricted cash included within other current and other long-term assets
    		                   
      total cash, cash equivalents, and restricted cash shown on the balance sheets
    		                   
      supplemental disclosure of non-cash investing and financing activities:
    		                   
      property and equipment purchases in accounts payable
    		                   
      purchase of intangible assets in exchange for in-licensing agreement payable
    		                   
      proceeds from debt and exercise of stock options
    		            231,000       
      payment of liability for in-licensing agreement
    		            0 940,000 -5,000,000 0 0   
      total cash, cash equivalents and restricted cash shown in the statement of cash flows
    		             244,897,000 570,718,000     
      property plant and equipment in accounts payable
    		             -207,000 2,353,000    423,000 
      proceeds from long-term debt and issuance of common shares pursuant to exercise of stock options
    		              1,941,000     
      restricted cash included in other long-term assets
    		              -937,000     
      repayment (issuance) of related party loans
    		                   
      repayment of long-term debt
    		               0 0 -107,000 -1,716,000 
      proceeds from long-term debt
    		               0 0   
      payment of contingent consideration
    		               0 0   
      short-term borrowings
    		                   
      issuance of common shares pursuant to exercise of stock options and other
    		                   
      repayment of loan to related parties
    		                   
      long-term investments and deposits
    		                   
      issuance of common shares pursuant to exercise of stock options
    		                898,000 1,710,000 173,000 
      proceeds from issuance of preferred shares - series a2 financing
    		                   
      cash and cash equivalents, beginning of period
    		                0 0 594,116,000 
      cash and cash equivalents, end of period
    		                -274,877,000 106,776,000 685,795,000 
      amortization of operating lease right-of-use-assets
    		                 693,000 661,000 
      long-term investments
    		                   
      other assets and liabilities
    		                  -1,924,000 
      investment in equity investees
    		                  -12,195,000 
      payment of deferred financing fees
    		                   
      extinguishment of long-term debt
    		                   
      accretion and other
    		                   
      unrealized foreign exchange gains and losses
    		                   
      investment tax credit receivable
    		                   
      acquisition of trianni
    		                   
      proceeds from issuance of preferred shares - series a1 financing
    		                   
      cash and cash equivalents, beginning of year
    		                   
      cash and cash equivalents, end of year
    		                   
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.